pharmaphorum

MARCH 17, 2022

The uptake of digital health tools during the pandemic has been enormous due to improved access they provide to healthcare. In this article, Ben Hargreaves asks whether there are gaps in those utilising these solutions and what action is being taken to address this. Digital health has a tremendous capacity to transform the healthcare industry, with the ability to provide easy access to a multitude of services and new types of therapies.

139

139

Pharma Times

MARCH 18, 2022

With the significant increase in entries this year, the competition to name the finalists proved incredibly tough. The International Clinical Researcher judging panel, however, have made their decisions and the finalists have now been announced.

111

111

Outsourcing Pharma

MARCH 14, 2022

The pharma company and academic institution will explore the viability of a psychedelic treatment to help patients suffering from cancer-related distress.

120

120

Drug Patent Watch

MARCH 16, 2022

Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Jazz Pharms drug XYREM appeared first on DrugPatentWatch - Make Better Decisions.

98

98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 13, 2022

The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown. The new approval is for use in patients with BRCA-mutated, HER2-negative early-stage breast cancer who have already been treated with chemotherapy – either before or after surgery – and are at high risk of the disease coming back.

Chemotherapy 123

Chemotherapy Labelling 123

Pharma Times

MARCH 15, 2022

COVID-19 has highlighted another significant widespread problem – the mental health pandemic

149

149

Drug Channels

MARCH 18, 2022

Today’s guest post comes from Ashwin Mundra, Chief Revenue Officer at Kalderos. As Ashwin explains, manufacturers face a gap between visible, non-compliant drug discounts and the actual level of non-compliant discounts. He describe Kalderos’ technology-enabled, machine learning-based methods for identifying drug discount non-compliance. To learn more, register to receive a copy of Kalderos’ annual report, available April 13, 2022: Conquering the “Great Unknown”: Connecting the data gaps that kee

84

84

pharmaphorum

MARCH 14, 2022

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing application. The US regulator has asked for additional clinical data, according to AZ, which said it remains committed to brining the drug to patients with the inflammatory condition, which results in the growth of nasal polyps in the nose that can sometimes require surgical intervention.

113

113

Pharma Times

MARCH 14, 2022

In the coming months, an additional vaccine booster will be offered to those over 75, care home residents and to those over 12 who are most vulnerable

Vaccines 119

Vaccines 119

Outsourcing Pharma

MARCH 16, 2022

An expert from the R&D tech provider discusses how automation, integration, and other tools can help with effective access and analysis of lab information.

93

93

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Drug Channels

MARCH 15, 2022

I am pleased to announce our new 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S.

Specialty Pharmacies 83

Specialty Pharmacies Drug Pricing Pharmaceutical Manufacturing Documentation 83

pharmaphorum

MARCH 15, 2022

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the development of therapies for Alzheimer’s disease and related dementias. According to the consortium – which includes drugmakers Biogen, Eisai, Eli Lilly and Merck & Co – there is a lack of measures that can be used to determine whether new therapies for Alzheimer’s are actually working.

Drug Development 102

Drug Development 102

Pharma Times

MARCH 17, 2022

The sub-variant combines mutations from both Omicron and Delta

172

172

Outsourcing Pharma

MARCH 16, 2022

While strides have been made recruiting more representative patient populations, more can and should be done, according to an Oracle Health Sciences leader.

92

92

Drug Patent Watch

MARCH 18, 2022

Annual Drug Patent Expirations for DEFINITY Definity is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Lantheus Medcl drug DEFINITY appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

MARCH 15, 2022

Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over full responsibility to its US counterpart. The changes to the terms of their longstanding collaboration on Aduhelm (aducanumab) means that Eisai’s profit-share converts to a simple royalty rate on revenues from 1 January next year.

102

102

Pharma Times

MARCH 18, 2022

The hybrid of Delta and Omicron, known as ‘Deltacron’, has been identified in France, Denmark and the Netherlands

128

128

Outsourcing Pharma

MARCH 16, 2022

A leader from the patient recruitment specialist discusses the industryâs ongoing challenges with patient population diversity, and potential solutions.

79

79

Drug Patent Watch

MARCH 18, 2022

Annual Drug Patent Expirations for DEFINITY+RT Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Lantheus Medcl drug DEFINITY RT appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

MARCH 15, 2022

The new normal is already here. Get used to it. The COVID-19 pandemic has radically disrupted traditional medical society conferences in a way that could scarcely have been imagined in 2019. The vast majority of societies were able to transition their planned physical events to virtual formats within remarkably short periods of time, and some delivered impressive attendee experiences.

Labelling 102

Labelling Vaccines Communication 102

Pharma Times

MARCH 16, 2022

Patients who were bedridden for seven days or longer were at increased risk of depression and anxiety over the study period

106

106

Outsourcing Pharma

MARCH 17, 2022

The medication adherence specialist is joining IT4Anxiety, a project focused on dealing with anxiety in patients with mental disorders, via technology.

59

59

Drug Patent Watch

MARCH 18, 2022

Annual Drug Patent Expirations for OXLUMO Oxlumo is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are eleven patents protecting this drug. This drug…. The post New patent for Alnylam Pharms drug OXLUMO appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

MARCH 18, 2022

Gaming industry veteran Jon David, responsible for highly-downloaded mobile games, including the Bejeweled and Plants vs Zombies franchises, has moved into the digital health arena by taking a senior position at Akili Interactive Labs. As Akili’s chief product officer, his role will be to make sure that the company’s game-based therapies are as engaging as “high-end entertainment,” ensuring that they are fun to play, as well as therapeutically effective.

95

95

Pharma Times

MARCH 16, 2022

Better treatment for conditions experienced by individuals who were exposed to alcohol before birth

111

111

Pharma Mirror

MARCH 18, 2022

HONG KONG, Sisram Medical Ltd (the “Company” or “Sisram”, stock code: 1696.HK; together with its subsidiaries referred as the “Group”), a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more, today announced its audited consolidated annual results for th

52

52

Pharma in Brief

MARCH 17, 2022

In a recently released decision , the Federal Court ( FC ) considered what happens when a patent infringement plaintiff agrees to resolve a dispute in a foreign jurisdiction, but continues to press parallel litigation against the same defendant in Canada. In this case, the defendant sought summary judgment based on the terms of a voluntary dismissal between the parties in the United States.

Documentation 52

Documentation 52

pharmaphorum

MARCH 15, 2022

Life science companies invest a significant number of resources to engage physicians and patient advocates. However, companies often fall short when it comes to engaging patients in a meaningful way during the product development process. In a new whitepaper, Best Practice Guide: Insights Management and Virtual Patient Engagement, Within3 provides a detailed roadmap to help life science companies navigate engagement in the virtual world.

95

95

Pharma Times

MARCH 18, 2022

Approval is significant as waning restrictions present significant threats to many immunocompromised people across the UK

98

98

Drug Patent Watch

MARCH 16, 2022

Annual Drug Patent Expirations for VIMPAT Vimpat is a drug marketed by Ucb Inc and is included in three NDAs. It is available from three suppliers. There is one patent…. The post New patent expiration for Ucb Inc drug VIMPAT appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Board Vitals - Pharmacist

MARCH 16, 2022

There’s no way around it, medical school is expensive and unfortunately for medical students, the costs have been increasing over the past several years. According to the Association of American Medical Colleges , the average cost of medical school including tuition, fees, and health insurance for first-year students attending in-state public schools in 2021-2022 was $39,237, a 29% increase from the cost in 2012-13 ($30,192).

Medical Schools 52

Medical Schools Documentation 52

pharmaphorum

MARCH 14, 2022

Janssen’s Roz Bekker, VP Commercial Strategy for Infectious Diseases & Vaccines at Janssen EMEA, looks at how COVID-19 has reinforced the value of connecting with people, and how healthcare systems need ongoing reform to deliver more holistic, human-centric care. The connecting effect of COVID-19. No matter where you are in the world, COVID-19 has had an impact.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Hospitals 93

Pharma Times

MARCH 17, 2022

The NHS has not met the 18-week target for people to receive planned treatment in England since February 2016

96

96

Drug Patent Watch

MARCH 16, 2022

Annual Drug Patent Expirations for ICLUSIG Iclusig is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Takeda Pharms drug ICLUSIG appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Birth Control Pharmacist

MARCH 14, 2022

Can pharmacy students advocate for pharmacists prescribing hormonal contraceptives? YES, that is exactly what Wilson Pace , a graduate of the University of Utah College of Pharmacy did. When Wilson heard about the barriers and costs that women experience when accessing contraceptives. His perseverance and dedication to advocacy as a pharmacy student allowed him to take action in his leadership class.

52

52